Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$9.88 -1.2%	$9.73	$2.20 ▼ $12.78	$270.48M	-0.58	206,882 shs	149,390 shs
PHVS Pharvaris	$22.14 -0.7%	$19.71	$11.51 ▼ $26.33	$1.16B	-2.81	78,029 shs	9,853 shs
SNDX Syndax Pharmaceuticals	$15.65 -0.6%	$10.35	$8.58 ▼ $22.50	$1.35B	0.74	2.25 million shs	714,850 shs
VERV Verve Therapeutics	$11.13	$10.55	$2.86 ▼ $11.40	$992.13M	2.23	3.94 million shs	N/A

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	0.00%	+1.73%	-0.10%	-7.50%	+114.26%
PHVS Pharvaris	0.00%	+10.83%	-4.09%	+33.61%	+18.93%
SNDX Syndax Pharmaceuticals	0.00%	+26.12%	+66.38%	+69.25%	-21.02%
VERV Verve Therapeutics	0.00%	0.00%	+2.02%	+154.69%	+148.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DBVT DBV Technologies	3.4254 of 5 stars	3.4	5.0	0.0	2.5	2.5	0.6
PHVS Pharvaris	2.4464 of 5 stars	3.5	4.0	0.0	2.4	0.8	0.0
SNDX Syndax Pharmaceuticals	4.0514 of 5 stars	4.5	0.0	4.4	3.2	0.8	0.0
VERV Verve Therapeutics	3.0841 of 5 stars	4.2	4.0	0.0	1.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	47.93% Upside
PHVS Pharvaris	3.00	Buy	$35.60	62.67% Upside
SNDX Syndax Pharmaceuticals	3.00	Buy	$38.00	139.84% Upside
VERV Verve Therapeutics	2.33	Hold	$14.57	30.92% Upside

Current Analyst Ratings Breakdown

Latest DBVT, SNDX, PHVS, and VERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	PHVS Pharvaris	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$55.00 ➝ $52.00
8/6/2025	SNDX Syndax Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/5/2025	SNDX Syndax Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$46.00 ➝ $51.00
8/5/2025	SNDX Syndax Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$43.00 ➝ $56.00
7/15/2025	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$37.00 ➝ $35.00
7/10/2025	SNDX Syndax Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$4.15M	65.81	N/A	N/A	$1.42 per share	7.02
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A
SNDX Syndax Pharmaceuticals	$23.68M	57.64	N/A	N/A	$3.38 per share	4.69
VERV Verve Therapeutics	$32.33M	30.69	N/A	N/A	$5.83 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$113.92M	-$4.77	N/A	N/A	N/A	-3,220.49%	-287.15%	-138.83%	11/5/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.36	N/A	N/A	N/A	N/A	-69.09%	-63.34%	N/A
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.89	N/A	N/A	N/A	-428.48%	-130.47%	-56.12%	11/4/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	N/A

Latest DBVT, SNDX, PHVS, and VERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q1 2025	PHVS Pharvaris	-$0.87	-$0.94	-$0.07	-$0.94	N/A	N/A
8/4/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$1.01	-$0.83	+$0.18	-$0.83	$26.64 million	$37.96 million
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.21	-$1.55	-$1.34	-$1.55	$0.64 million	$1.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	2.45	2.45
PHVS Pharvaris	N/A	8.33	8.33
SNDX Syndax Pharmaceuticals	2.06	4.71	4.55
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
PHVS Pharvaris	N/A
SNDX Syndax Pharmaceuticals	N/A
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.44%
PHVS Pharvaris	N/A
SNDX Syndax Pharmaceuticals	4.10%
VERV Verve Therapeutics	19.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
PHVS Pharvaris	30	52.29 million	N/A	Not Optionable
SNDX Syndax Pharmaceuticals	110	86.14 million	82.61 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.94 million	Optionable

DBVT, SNDX, PHVS, and VERV Headlines

Recent News About These Companies

Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Thursday

August 13, 2025 | americanbankingnews.com

Canaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

August 9, 2025 | theglobeandmail.com

Verve Therapeutics Announces Merger and Nasdaq Delisting

August 3, 2025 | theglobeandmail.com

GSA Capital Partners LLP Buys 78,768 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

August 2, 2025 | marketbeat.com

Gene Therapy Companies Set Sights on Cardiovascular Disease

August 1, 2025 | genengnews.comG

Y Intercept Hong Kong Ltd Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

July 31, 2025 | marketbeat.com

Cwm LLC Purchases 24,841 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

July 30, 2025 | marketbeat.com

Cerity Partners LLC Invests $110,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)

July 30, 2025 | marketbeat.com

Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102

July 29, 2025 | msn.com

Eli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 26, 2025 | finanznachrichten.de

Verve Therapeutics (NASDAQ:VERV) Upgraded to "Hold" at Wall Street Zen

July 26, 2025 | marketbeat.com

Eli Lilly completes acquisition of Verve Therapeutics

July 25, 2025 | msn.com

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 25, 2025 | prnewswire.com

Lilly and Verve announce expiration of Verve tender offer

July 24, 2025 | prnewswire.com

Penn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli Lilly

July 24, 2025 | msn.com

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

July 24, 2025 | finance.yahoo.com

3 Bullish Biotech Stocks With Explosive Growth Trends

...

July 21, 2025 | marketbeat.com

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing

July 16, 2025 | thepharmaletter.comT

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)

...

July 15, 2025 | marketbeat.com

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

July 14, 2025 | msn.com

Biotech Stocks Are Ready to Rebound. 3 to Watch Now.

July 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DBVT, SNDX, PHVS, and VERV Company Descriptions

DBV Technologies NASDAQ:DBVT

$9.88 -0.12 (-1.15%)

As of 12:27 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Pharvaris NASDAQ:PHVS

$22.14 -0.16 (-0.72%)

As of 12:27 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Syndax Pharmaceuticals NASDAQ:SNDX

$15.65 -0.09 (-0.58%)

As of 12:28 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Verve Therapeutics NASDAQ:VERV

$11.13 0.00 (0.00%)

As of 07/25/2025

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time